Delisting Determination, The Nasdaq Stock Market, LLC,
December 17, 2019, Novelion Therapeutics Inc. The Nasdaq
Stock Market LLC (the Exchange) has determined to remove
from listing the common stock of Novelion Therapeutics Inc.
(the Company), effective at the opening of the trading
session on December 27, 2019. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5250(c)(1).
The Company was notified of the Staff determination on
August 21, 2019.  The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
October 7, 2019, denying the Company continued listing
and notified the Company that trading in the Company
securities would be suspended on October 9, 2019.
The Company did not request a review of the Panel decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panel Determination to delist the Company
became final on November 21, 2019.